Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.46 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | DRD4 | P21917 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3139557 | 0.89 | DRD4 (0.48) | DRD2HTR1AADRA1ADRD4 | |
| SCHEMBL3157190 | 0.89 | CCR2 (0.52) | DRD2DRD3DRD4ALDH1A1SMN1; SMN2 | |
| SCHEMBL3153260 | 0.86 | DRD3 (0.43) | DRD2DRD3HTR1A | |
| SCHEMBL3155096 | 0.86 | DRD2 (0.45) | DRD2DRD3HTR1AADRA1ADRD4 | |
| SCHEMBL15016168 | 0.85 | DRD4 (0.49) | DRD2DRD3DRD4ALDH1A1SMN1; SMN2 | |
| SCHEMBL3139317 | 0.84 | CA1 (0.49) | DRD2DRD3HTR1ADRD4SMN1; SMN2 | |
| SCHEMBL3149168 | 0.84 | F10 (0.53) | DRD2DRD3DRD4ALDH1A1SMN1; SMN2 | |
| SCHEMBL3153306 | 0.84 | DRD2 (0.48) | DRD2DRD4 | |
| SCHEMBL3140843 | 0.82 | DRD4 (0.51) | DRD2DRD3DRD4 | |
| SCHEMBL3153224 | 0.81 | CCR2 (0.57) | DRD2HTR1AADRA1AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2074083-B1 | NEW SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT (HU) | 2013-06-19 | — | — | EP | disclosed |
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | RICHTER GEDEON NYRT. (HU) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075978-A1 | SULFONAMIDE DERIVATIVES AS BRADYKININ ANTAGONISTS | BDKRB1, BDKRB2, TRPV1 | DRD2 424/4885DRD3 467/4885HTR1A 709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.